中国临床药学杂志2026，Vol.35Issue(1)：7-12,6.DOI:10.19577/j.1007-4406.2026.01.002
酒精相关性肝病患者药物治疗管理路径的建立
Establishment of medication therapy management pathway for patients with alcohol-associated liver disease
摘要
Abstract
AIM To establish a pharmacist-led medication therapy management(MTM)pathway for patients with alcohol-associated liver disease(ALD),providing a reference for MTM in ALD patients.METHODS Based on the clinical evidence,clinical guidelines and related literature,we systematically reviewed and synthesized the key principles of pharmacotherapy,common adverse drug reactions,essential monitoring parameters,and critical elements of long-term follow-up for patients with ALD.RESULTS A structured clinical guidance pathway was developed from the pharmacist's perspective,which encompassed the entire continuum of care,from initial medication reconciliation and risk assessment to ongoing long-term follow-up.CONCLUSION The established MTM pathway for ALD patients can provide evidence-based medicine and pharmaceutical basis for MTM in clinical to promote rational drug use,improve patient medication compliance and ensure patient medication safety.关键词
酒精相关性肝病/保肝药/药物治疗管理Key words
alcohol-associated liver disease/hepatoprotective agents/medication therapy management分类
医药卫生引用本文复制引用
姜康,吴斌,霍炎,赵琼玥,毛叶萌,冉姗,刘晓东,顾董事,兰延文,张宁,吕迁洲,姚继红,蒋淼,高振明,蔡爽,黄滔敏,高鹏飞..酒精相关性肝病患者药物治疗管理路径的建立[J].中国临床药学杂志,2026,35(1):7-12,6.基金项目
上海市卫健委卫生行业临床研究专项(编号202340281) （编号202340281）
